Immunosuppressive agents in skin disorders a comparative review

Clinical Immunotherapeutics

Volumn 5, Issue 4, 1996, Pages 268-293

  Dutz, Jan P ^a   Ho, Vincent C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

BLOOD TOXICITY; CONNECTIVE TISSUE DISEASE; ECZEMA; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; PEMPHIGUS; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN DISEASE; VASCULITIS;

EID: 0029870034     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259327     Document Type: Article

References (272)

1. Ho VC, Zloty DM, Immunosuppressive agents in dermatology, Dermatol Clin 1993; 11: 73-85
2. Elion GB, The George Hitchings and Gertrude Elion Lecture, The pharmacology of azathioprine. Ann NY Acad Sei 1993; 685: 400-7
3. Chan GLC, Erdmann GR, Gruber SA, et al, Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients, J Clin Pharmacol 1990; 30: 358-63
4. Ohlman S, Albertioni F, Peterson C, Day-to-day variability in azathioprine pharmacokinetics in renal transplant patients, ClinTranspl 1994; 8: 217-23
5. Snow JL, Gibon LE, A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologie patients, J Am Acad Dermatol 1995; 32: 114-6
6. Weinshilboum RM, Sladek SL, Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity, Am J Hum Genet 1980; 32:651 -62
7. Snow JL, Gibon LE, The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologie patients, Arch Dermatol 1994: 130: 1-6
8. Lennard L, Van Loon JA, Weinshilboum RM, Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-54
9. Kerstens PJ, Stolk JN, Hilbrands LB, et al. 5-Nucleotidase and azathioprine-related bone-marrow toxicity [letter]. Lancet 1993:342: 1245-6
10. Anstey A, Azathioprine in dermatology: a review in light of advances in understanding methylation pharmacogenetics. J R Soc Med 1995; 88: I55P-66P
11. Baadsgaard O, Circulating and in situ lymphocyte subsets and Langerhans cells in patients with compositae oleoresin dermatitis and increased ultraviolet A sensitivity during treatment with azathioprine. J Am Acad Dermatol 1986; 14: 577-81
12. Pedersen BK, Abom B, The in vivo effect of triethylphosphine gold (auranofin), sodium aurothiomalate and azathioprine on lymphocyte subsets of patients with rheumatoid arthritis. Allergy 1988:43: 396-8
13. Bliven ML, Cunningham AC, Otterness IG. A pharmacologie study of the relationship between lymphocyte function and surface antigen expression. Agents Actions 1988; 25: 86-93
14. Al-Safi SA, Maddocks JL, Effects of azathioprine on the mixed lymphocyte reaction (MLR). Br J Clin Pharmacol 1983; 15: 203-9
15. Dayton JS, Turka LA, Thompson CB, et al, Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism. Moi Pharmacol 1992; 41:671-6
16. Pedersen BK, Beyer JM, A longitudinal study of the influence of azathioprine on natural killer cell activity. Allergy 1986; 41: 286-9
17. Stohl W, Impaired polyclonal T cell cytolytic activity, a possible risk factor for systemic lupus erythematosus. Arthritis Rheum 1995; 38: 506-16
18. Younger IR, Harris DWS, Colver GB, Azathioprine in dermatology. J Am Acad Dermatol 1991; 25: 281-6
19. Murthy SNS, Anania T, Clearfield HR, Azathioprine reduces extravasation and neutrophil trafficking in immune complexmediated inflammation in the rat colon. Agents Actions 1991 ; 34: 243-6
20. DiStefanoR, Scavuzzo M, Pietrabissa A, etal. Effect of immunosuppressive regimens on neutrophil chemotaxis. Transpl Proc 1994; 26: 2861-2
21. Barrera P, Boerbooms AM, Sauerwein RW, et al, Interference of circulating azathioprine but not methotrexate or sulfasalazine with measurements of interleukin-6 bioactivity. Lymphokine Cytokine Res 1994; 13: 155-9
22. Anstey A, Lennard L, Mayou SC, et al. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med 1992; 85: 752-6
23. Aberer W, Wolff-Schreiner EC, Siingl G. et al. Azathioprine in the treatment of pemphigus vulgaris. J Am Acad Dermatol 1987; 16: 527-33
24. Singh G, Fries JF, Spitz P, etal, Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. Arthritis Rheum 1989; 32: 837-43
25. Guillaume JC, Vaillant L, Bernard P, et al, Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullouspemphigoid. ArchDermatol 1993; 129:49-53
26. Mion F, Napoleon B, Berger F, et al. Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 1991:32: 715-7
27. Finals RS, Azathioprine in the treatment of chronic polyarthritis: longterm results and adverse effects in 25 patients. J Rheumatol 1976; 3: 140-4
28. Murdock DK, Lookingbill DP, Immunosuppressive therapy of pemphigus vulgaris complicated by nocardia pneumonia. Arch Dermatol 1990; 126: 27-8
29. Penn I, Halgrimson CG, Starzl TE, De novo malignant tumors in organ transplant recipients. Transpl Proc 1971; 3: 773-8
30. Penn I, Cancer in immunosuppressed patients. Transpl Proc 1984; 16:492-4
31. Silman AJ, Pétrie J, Hazleman B, et al, Lymphoproliferative cancer and other malignancies in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow-up study. Ann Rheum Dis 1988; 47: 988-92
32. Amato MP, Pracucci G, Ponziani G, et al, Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 1993: 43:831-3
33. Connell WR, Kamm MA, Dickson M, et al, Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-52
34. Larvol L, Soûle JC, LeTourneau A, Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease (letter]. N Engl J Med 1994; 331: 883-4
35. Briggs GO, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, a reference guide to fetal and neonatal risk. 4th ed. Baltimore: Williams & Wilkins, 1994
36. Friedman JM, Polifka JE, Teratogenic effects of drugs, a resource for clinicians. Baltimore: John Hopkins University Press, 1994
37. Davidson JM, Lindheimer MD, Pregnancy in women with renal allografts. Semin Nephrol 1984; 4: 240-51
38. Davidson JM, Dellagrammatikas H. Parkin JM. Maternal azathioprine therapy and depressed haematopoesis in the babies of renal allograft patients. Br J Obstet Gynaecol 1985; 92: 233-9
39. Saway PA, Heck LW, Bonner JR, et al. Azathioprine hypersensitivity. Am J Med 1988: 84: 960-4
40. Rivier G, Khamashta MA, Hughes GR, Warfarin and azathioprine: a drug interaction does exist [letter; comment]. Am J Med 1993; 95: 342
41. Moore MJ, Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991; 20: 194-208
42. Calabresi P, Parks Jr RE. Antiproliferative agents and drugs used for immunosuppression. In: Oilman AG. Goodman LS, Rail TW, et al., editors. The pharmacological basis of therapeutics. New York: Macmillan Publishing Co, 1985: 1256-313
43. Fox DA, McCune WJ. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994; 20: 265-93
44. Ahmed AR, Hombal S, Cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol 1987; 17: 437-42
45. McCune W, Golbus J, Zeldes W, et al, Clinical and immunologie effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl JMed 1988; 318: 1423-31
46. Takeno M, Suzuki N, Nagafuchi H, et al. Selective suppression of resting B cell function in patients with systemic lupus er-ythematosus treated with cyclophosphamide. Clin Exp Rheumatol 1993; 11:263-70
47. Yasunami R, Bach JF, Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 1988; 18: 481-4
48. Bersani-Amado CA, Duarte AJ, Tanji MM, et al, Comparative study of adjuvant induced arthritis in susceptible and resistant strains of rats. III. Analysis of lymphocyte subpopulations. J Rheumatol 1990; 17: 153-8
49. Marcinkiewicz J, Bryniarski K, Ptak W, Cyclophosphamide uncovers two separate macrophage subpopulations with opposite immunogenic potential and different patterns of monokine production. Cytokine 1994; 6: 472-7
50. Levine LA, Richie JP, Urologie complications of cyclophosphamide. J Urol 1989; 141: 1063-9
51. Bennett AH, Cyclophosphamide and hemorrhagic cystitis. J Urol 1974; 111:603
52. Stillwell TJ, Benson Jr RC, Cyclophosphamide-induced hemorrhagic cystitis - a review of 100 patients. Cancer 1988; 61 : 451-7
53. Kolb NS, Hunsaker LA, Vander Jagt DL, Aldose reductasecatalyzed reduction of acrolein: implications in cyclophosphamide toxicity. Mol Pharmacol 1994; 45: 797-801
54. How JM, Mehta A, Ward L, et al, Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomized study. Br J Cancer 1984; 50: 753-6
55. Fairchild WV, Spence CR, Soloman HD, The incidence of bladder cancer after cyclophosphamide therapy. J Urol 1979; 122: 163-4
56. Stein JP, Skinner EC, Boyd SD, et al, Squamous cell carcinoma of the bladder associated with cyclophosphamide therapy for Wegener's granulomatosis: a report of 2 cases. J Urol 1993; 149: 588-9
57. Zonzits E, Aberer W, Tappeiner G, Drug eruptions from mesna. Arch Dermatol 1992; 128: 80-2
58. Shepherd JD, Pringle LE, Barnett MJ, et al, Mesna versus hyperhydration for the prevention of cyclophosphamideinduced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1990; 9: 2016-20
59. Bradley JD, Brandt KD, Katz BP, Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32: 45-53
60. Porter DR, Marshall DA, Madhok R, et al, Pneumocystis carinii infection complicating cytotoxic therapy in two patients with lymphopenia, but a normal total white cell count. Br J Rheumatol 1992; 31: 71-2
61. Jarrousse B, Guillevin L, Bindi P, et al, Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 1993; 11:615-21
62. Bakus JA, The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow up. Ann Rheum Dis 1983; 42: 368-73
63. Baker Gl, Kahl LE, Zee BC, Malignancy following treatment of rheumatoid arthritis with cyclophosphamide; long-term case-control follow-up study. Am J Med 1987; 83: 1-9
64. Kovarsky J, Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Semin Arthritis Rheum 1983; 12: 359-68
65. Langevitz P, Klein L, Präs M, et al, The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 1992; 28: 157-8
66. Boumpas DT, Austin III HA, Vaughan EM, et al, Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-9
67. Bannwarth B, Labat L, Moride Y, et al, Methotrexate in rheumatoid arthritis: an update. Drugs 1994; 47: 25-50
68. Herman RA, Veng-Pedersen P, Hoffman J, et al, Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sei 1989; 78: 165-71
69. Ongey D, Këlliker F, Gerber NJ, et al, Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 611-4
70. Zachariae H, Methotrexate side-effects. Br J Dermatol 1990; 122: 127-33
71. McLaughlin GE, Parenteral versus oral methotrexate: a cost comparison. Arthritis Rheum 1994; 37: 779
72. Balis FM, Mirro J, Reaman GH, et al, Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988; 6: 1882-6
73. Brooks PJ, Spruill WJ, Parish RC, et al, Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 91-4
74. Seideman P, Beck O, Eksborg S, et al, The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993; 35: 409-12
75. Jeffes III EWB, McCullough JL, Pittelkow MR, et al, Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995; 104: 183-8
76. Kremer JM, The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 1994; 21: 1-5
77. Cronstein BN, Naime D, Ostad E, The antiinflammatory mechanism of methotrexate. J Clin Invest 1993; 92: 2675-82
78. Sperling RI, Benincaso AI, Andersen RJ, et al, Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 1992; 35: 376-84
79. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, et al, Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204-10
80. alAwadhi A, Dale P, McKendry RJ, Pancytopenia associated with low dose methotrexate therapy. A regional survey. J Rheumatol 1993; 20: 1121-5
81. Morgan SL, Baggott JE, Alarcôn GS, et al, The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990:33:9-18
82. Morgan SL, Baggott JE, Vaughn WH, et al, Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 1994; 121: 833-41
83. Schiroky JB, Neville C, Esdaile JM, et al, Low dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double blind, placebo controlled trial. Arthritis Rheum 1993; 36: 795-803
84. Hills RJ, Ive FA, Folinic acid rescue used routinely in psoriatic patients with known methotrexate 'sensitivity'. Acta Derm Venereol 1992:72:438-40
85. Stenger AAME, Houtman PM, Bruyn GA, Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate? Ann Rheum Dis 1992; 51: 1019-20
86. Chrcn M-M, Casserly CM, Strange KC, Folie acid supplementation with methotrexate therapy: what benefit if any? [letter], J Am Acad Dermatol 1994; 31: 689
87. Duhra P, Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28: 466-9
88. Dubin DB, Dover JS, Making methotrexate therapy more palatable. Fitzpatrick's J Clin Dermatol 199S; 3: 48-57
89. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologie hepatic abnormalities: a meta-analysis. Am J Med 1991:90:711-6
90. Auerbach R, Psoriasis symposium. Methotrexate. Semin Dermatol 1992; 11: 23-9
91. Themido R, Loureiro M. Pecegueiro M. et al. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol 1992; 72: 361-4
92. Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Arch Dermatol 1989; 125: 1218-24
93. Gilbert SC, Klintmalm G, Mentor A, et al. Methotrexate induced cirrhosis requiring liver transplantation in three patients with psoriasis. Arch Intern Med 1990; 150: 889-91
94. Roenigk Jr HH, Auerbach R, Maihach HI, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988: 19: 145-56
95. Petrazzuoli M, Rothe MJ, Grin-Jorgensen C, et al, Monitoring patients taking methotrexate for hepatotoxicity. J Am Acad Dermatol 1994:31:969-77
96. Rothe MJ, Grin-Jorgensen C. Ramsey WH, et al. Monitoring patients taking methotrexate. J Am Acad Dermatol 1995; 32: 680
97. Goodman TA, Polisson RP, Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 1994; 20: 513-29
98. Lemense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994; 150: 258-60
99. Boerbooms AMT, Kerstens PJSM, van Loenhout JWA, et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24: 411-21
100. Weinstein GD, Frost P. Methotrexate for psoriasis. Anew therapeutic approach. Arch Dermatol 1971; 103: 33-8
101. Kamel OW, van de Rijn M, Weiss LM, et al, Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis [see comments]. N Engl J Med 1993: 328: 1317-21
102. Stern RS, Laird N, The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73: 2759-64
103. Morris LF, Harrod MJ, Menter MA. et al. Methotrexate and reproduction in men: case report and recommendations. J Am Acad Dermalol 1993; 29: 913-6
104. Ko/lowski RD, Steinbrunner JV, Mackenzie AH, et al, Outcome of first exposure to low dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88: 589-92
105. Donnenfeld AE, Pastuszak A, Noah JS. et al. Methotrexate exposure prior and during pregnancy [letter|. Teratology 1994: 49: 79-81
106. Andersen WK, Feingold DS. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol 1995: 131:468-73
107. Kovarik JM, MuellerEA, van Bree JB.etal. Reduced inter-and intraindividual variability in cyclosporin pharmacokinetics from a microemulsion formulation. J Pharm Sei 1994; 83: 444-6
108. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993: 45:953-1040
109. Liu J, FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993: 14: 290-5
110. Wong RL, Winslow CM, Cooper KD, The mechanisms of action of cyclosporin A in the treatment of psoriasis (review]. Immunol Today 1993; 14:69-74
111. Mason J, Renal side-effects of cyclosporin A. Br J Dermatol 1990; 122Suppl. 36: 71-7
112. Feutren G, Mihatsch M, Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992; 326: 1654-60
113. Feutren G, Abeywickrama K, Friend D, et al, Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol 1990; 122 Suppl. 36: 57-69
114. Powles AV, Cook T, Hulme B, et al, Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis. BrJ Dermatol 1993; 128: 159-65
115. Pei Y, Scholey JW, Katz A, et al. Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporin. Am J Kidney Dis 1994; 23: 528-36
116. Young E, EllisC, Messana J. et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 1994; 46: 1216-22
117. Krupp P, Monka C, Side effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol 1990; 122 Suppl. 36: 47-56
118. FradinM, EllisC, Voorhees J. Management of patients and side effects during cyclosporin therapy for cutaneous disorders. J Am Acad Dermatol 1990; 23: 1265-75
119. Ryffel B, Mihatsch MJ, Fisher GL, Immunosuppression and cancer: the cyclosporin case. Drug Chem Toxicol 1992: 15: 95-115
120. Watkins PB, The role of cytochrome P-450 in cyclosporin metabolism. J Am Acad Dermatol 1990:23: 1301-11
121. Yee GC, Pharmacokinetic interactions between cyclosporin and other drugs. Transplant Proc 1990; 22: 1203-7
122. Kauvar AB, Stiller MJ. Cyclosporin in dermatology: pharmacology and clinical use [review]. Int J Dermatol 1994; 33: 86-96
123. Bystryn J-C, Adjuvant therapy of pemphigus. Arch Dermatol 1984; 120: 941-51
124. Roenigk HH, Doedhar S. Pemphigus treatment with azathioprine. Clinical and immunoloeical correlation. Arch Dermatol 1973: 107: 353-7
125. Ebringer A, McKay IR, Pemphigus vulgaris successfully treated with cyclophosphamide. Ann Intern Med 1969: 71: 125-7
126. Fellner M, Katz JM. Mccabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol 1978; 114: 889-94
127. Pasricha JS, Thanzama J, Khan UK, Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol 1988; 119:73-7
128. Kaur S, Kanwar AJ, Dexamethasone-cvclophosphamide pulse therapy in pemphigus. Int J Dermatol 1990; 29: 371-4
129. Pasricha JS, Das SS. Curative effect of dexamethasone-cyclophosphamide therapy for the treatment of pemphigus vulgaris. Int J Dermatol 1992: 31: 875-7
130. Pandya AG, Sontheimer RD, Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol 1992; 128: 1626-30
131. Appelhans M, Bonsmann G, Orge C, et al, Dexamethasonecyclophosphamide pulse therapy in bullous autoimmune dermatoses [in German]. Hautarzt 1993; 44: 143-7
132. Jablonska S, Chorzelski T, Blaszczyk M, Immunosuppressants in the treatment of pemphigus. Br J Dermatol 1970; 83: 315-22
133. Lever WF, Goldberg S, Treatment of pemphigus vulgaris with methotrexate. Arch Dermatol 1969; 100: 70-8
134. Lever WF, Schaumburg-Lever G, Immunosuppressants and prednisone in pemphigus vulgaris. Arch Dermatol 1977; 113: 1236-41
135. Barthélémy H, Frappaz A, Cambazard F, et al, Treatment of nine cases of pemphigus vulgaris with cyclosporin. J Am Acad Dermatol 1988; 18: 1262-6
136. Alijotas J, Pedragosa R, Bosch J, et al, Prolonged remission after cyclosporin therapy in pemphigus vulgaris: report of two young siblings. J Am Acad Dermatol 1990; 23: 701-3
137. Lapidoth M, David M, Ben Amitai D, et al, The efficacy of combined treatment with prednisone and cyclosporin in patients with pemphigus: preliminary study. J Am Acad Dermatol 1994; 30: 752-7
138. Chrysomallis F, loannides D, Teknetzis A, et al, Treatment of oral pemphigus vulgaris. Int J Dermatol 1994; 33: 803-7
139. Burton JL, Greaves MW, Azathioprine for pemphigus and pemphigoid. A 4 year follow up. Br J Dermatol 1974; 91: 103-9
140. Burton JL, Harmann RMM, Peachey RDG, et al, A controlled study of azathioprine in the treatment of pemphigoid. Br J Dermatol 1978; 99 Suppl. 16: 14
141. Mondino BJ, Brown SI, Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol 1983; 96: 453-9
142. Lamey PJ, Rees TD, Binnie WH, et al, Mucous membrane pemphigoid. Treatment experience at two institutions. Oral Surg Oral Med Oral Pathol 1992; 74: 50-3
143. Warren SD, Lesher JLJ, Cicatricial pemphigoid. South Med J 1993; 86: 461-4
144. Yong AS, Elborn JS, Stanford CF, Cicatricial pemphigoid presenting as upper airways obstruction. Br J Clin Pract 1994; 48: 47-8
145. Ahmed AR, Hombal SM, Cyclophosphamide (Cytoxan): a review of relevant pharmacology and clinical uses. J Am Acad Dermatol 1984; 11: 1115-26
146. Anhalt GJ, Pemphigoid. Bullous and cicatricial [review]. Dermatol Clin 1990; 8: 701-16
147. Paul MA, Jorizzo JL, Fleischer AJ, et al, Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1994; 31: 620-5
148. Boixeda JP, Sorina C, Medina S, et al, Bullous pemphigoid and psoriasis: treatment with cyclosporin. J Am Acad Dermatol 1991; 24: 152
149. Bianchi L, Gatti S, Nini G, Bullous pemphigoid and severe erythrodermic psoriasis: combined low-dose treatment with cyclosporin and systemic steroids [letter]. J Am Acad Dermatol 1992; 27: 278
150. Azana JM, de Misa RF, Boixeda JP, et al, Topical cyclosporin for cicatricial pemphigoid [letter; comment]. J Am Acad Dermatol 1993; 28: 134-5
151. Connolly SM, Sander HM, Treatment of epidermolysis bullosa acquisita with cyclosporin [letter]. J Am Acad Dermatol 1987 ; 16: 890
152. Zachariae H, Cyclosporin A in epidermolysis bullosa acquisita [letter]. J Am Acad Dermatol 1987; 17: 1058-9
153. Crow LL, Finkle JP, Gammon WR, et al, Clearing of epidermolysis bullosa acquisita with cyclosporin [see comments!. J Am Acad Dermatol 1988; 19: 937-42
154. Layton AM, Cunliffe WJ, Clearing of epidermolysis bullosa acquisita with cyclosporin [letter; comment]. J Am Acad Dermatol 1990:22:535-6
155. Austin III HA, Klippe! JH, Balow JE, et al, Therapy of lupus nephritis: controlled trial of prednisone and cylotoxic drugs. N Engl J Med 1986; 314: 614-9
156. Ginzler E, Sharon E, Diamond H, et al, Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 1975; 18: 27-34
157. Hahn BH, Kantor OS, Osterland CK, Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann Intern Med 1975; 83: 597-605
158. Boumpas DT, Austin III HA, Vaughn EM, et al, Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741-5
159. Neuwelt CM, Lacks S, Kaye BR, et al, Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatrie systemic lupus erythematosus. Am J Med 1995; 98: 32-41
160. Wilke WS, Krall PL, Scheetz RJ, et al, Methotrexate for systemic lupus erythematosus: A retrospective analysis of 17 unselected cases. Clin Exp Rheumatol 1991; 9: 581-7
161. Wilson K, Abeles M, A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21: 1674-7
162. Walz-LeBlanc BA, Dagenais P, Urowitz MB, et al, Methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21: 836-8
163. Rothenberg RJ, Graziano FM, Grandote JT, et al, The use of methotrexate in steroid resistant systemic lupus erythematosus. Arthitis Rheum 1988; 31:612-5
164. Favre H, Miescher P, Huang Y, et al, Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 1989; 9 Suppl. 1: 57-60
165. Feutren G, Quérin S, Tron F, et al, The effects of cyclosporin in patients with systemic lupus. Transplant Proc 1986; 18:643-4
166. Blank M, Ben-Bassat M, Shoenfeld Y, The effect of cyclosporin A on early and late stages of experimental lupus. Arthritis Rheum 1992; 35: 1350-5
167. Tokuda M, Kurata N, Mizoguchi A, et al, Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994; 37: 551-8
168. Callen JP, Treatment of cutaneous lesions in patients with lupus erythematosus. Dermatol Clin 1994; 12: 201-6
169. Tsokos GC, Caughman SW, Klippel JH, Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Arch Dermatol 1985; 121: 1323-5
170. Shehade S, Successful treatment of generalized discoid skin lesions with azathioprine. Arch Dermatol 1986; 122: 376-7
171. Ashinoff R, Werth VP, Franks Jr AG, Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 1988; 19: 961-4
172. Callen JP, Spencer LV, Burruss JB, et al, Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991; 127:515-22
173. Goldstein E, Carey W, Discoid lupus erythematosus: successful treatment with oral methotrexate [letter|. Arch Dermatol 1994; 130:938-9
174. Yell JA, Bürge SM, Cyclosporin and discoid lupus erythematosus [letter]. Br J Dermatol 1994; 131: 132-3
175. Dalakas MC, Polymyositis, dermatomyositis, and inclusionbody myositis. N Engl J Med 1991; 325: 1487-98
176. Bunch TW, Worthington J W, Coombs J, et al, Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 1980; 92: 365-9
177. Bunch TW, Prednisone and azathioprine for polymyositis: longterm followup. Arthritis Rheum 1981; 24: 45-8
178. Metzger AL, Bohan A, Goldberg L, et al, Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81: 182-9
179. Joffe MM, Love LA, Leff RL, et al, Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine. and methotrexate and a comparison of their efficacy. Am J Med 1993; 94: 379-87
180. Zieglschmid-Actams ME, Pandya AG, Cohen SB, et al, Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 1995; 32:754-7
181. Bombardier! S, Hughes GRV, Neri R, et al, Cyclophosphamide in severe polymyositis. Lancet 1989; i: 1138-9
182. Heckmatt J, HassonN, SaudersC, etal, Cyclosporin in juvenile dermatomyositis. Lancet 1989; i: 1063-6
183. Lueck CJ, Trend P, Swash M, Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991; 54: 1007-8
184. Stedeford J, Wordsworth BP, Cyclosporin A treatment of dermatomyositis [letter]. Arthritis Rheum 1991; 34: 933
185. CorreiaO, PoloniaJ, Nunes JP, etal, Severe acute form of adult dermatomyositis treated with Cyclosporin. Int J Dermatol 1992:31:517-9
186. Mehregan DR, Su WP, Cyclosporin treatment for dermatomyositis/polymyositis. Cutis 1993; 51: 59-61
187. Pistoia V, Buoncompagni A, Scribanis R, et al, Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study [see comments]. Clin Exp Rheumatol 1993; 11: 203-8
188. Grau JM, Herrero C, Casademont J, et al, Cyclosporin A as first choice therapy for dermatomyositis [letter], J Rheumatol 1994; 21: 381-2
189. Herrmann K, Haustein U-F, Immunologie parameters in systemic sclerosis. Int J Dermatol 1994; 33: 25-32
190. Medsger TA, Treatment of systemic sclerosis. Ann Rheum Dis 1991:50:877-86
191. Steen V, Treatment of systemic sclerosis. Curr Opin Rheumatol 1991; 3: 979-85
192. Akesson A, Scheja A, Lundin A, et al. Improved pulmonary function in systemic sclerosis after treatment with Cyclophosphamide. Arthritis Rheum 1994; 37: 729-35
193. Silver RM, Warrick JH, Kinsella MB, et al, Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838-44
194. Zachariae H, Zachariae E, Cyclosporin A in systemic sclerosis. BrJ Dermatol 1987; 116:741-2
195. Clements PJ, Lachenbruch PA. Sterz M, et al. Cyclosporin in systemic sclerosis. Results of a forty-eight week open safety study in ten patients. Arthritis Rheum 1993; 36: 75-83
196. Denton CP, Sweny P, Abdulla A, et al. Acute renal failure occurring in scleroderma treated with Cyclosporin A: a report of three cases [review]. BrJ Rheumatol 1994: 33: 90-2
197. Peter RU, Ruzicka T, Eckert F, Low-dose cyclosporin A in thé treatment of disabling morphea [letter]. Arch Dermatol 1991 ; 127: 1420-1
198. Bos JD, Kapsenberg ML, Smitt JHS, Pathogenesis of atopic eczema. Lancet 1994; 343: 1338-41
199. Leigh IM, Hawk JL. Treatment of chronic actinic dermatitis with azathioprine. Br J Dermatol 1984; 110: 691-5
200. Murphy GM, Maurice PDL, Morris PC, et al, Azathioprine treatment in chronic actinic dermatitis: a double-blind controlled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol 1989; 121: 639-46
201. Morrison JGL, Schulz EG, Treatment of eczema with cyclophosphamide and azathioprine. Br J Dermatol 1978; 98: 203-7
202. Sowden JM, Berth JJ, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis [see comments). Lancet 1991; 338: 137-40
203. van Joost T, Heule F, Korstanje M, et al, Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994: 130:634-40
204. Camp RDR, Reitamo S, Friedman PS, et al, Cyclosporin A in severe, therapy-resistant atopic dermatitis: report of an international workshop. BrJ Dermatol 1993; 129: 127-220
205. Graniund H, Erkko P. Sinisalo M, et al. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. BrJ Dermatol 1995; 132: 106-12
206. Gardeazâbal J, Arregui MA, Gil N, et al. Successful treatment of musk ketone-induced chronic actinic dermatitis with cyclosporin and PUVA. J Am Acad Dermatol 1992; 27: 838-42
207. Norris PG, Camp RDR, Hawk JLM, Actinic reticuloid: response to cyclosporin. J Am Acad Dermatol 1989: 21: 307-9
208. Callen JP, Ekenstam E, Cutaneous leukocytoclastic vasculitis. Clinical experience in 44 patients. South Med J 1987; 80: 848-51
209. Cooper BJ, Bacal E, Patterson T. Allergic angiitis and granulomatosis. Prolonged remission induced by combined prednisone-azathioprine therapy. Arch Intern Med 1978; 138: 376-81
210. Leib ES, Restivo C, Paulus HE, Immunosuppressive and corticosteroid therapy for polyarteritis nodosa. Am J Med 1979; 67:941-7
211. Heurkens AHM, Westedt ML, Breedveld FC, Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 1991; 151: 2249-54
212. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990: 322: 281-5
213. Lingenfelser T, Duerk H, Stevens A, et al. Generalized myosilis in Behcet disease: treatment with cyclosporin. Ann Intern Med 1992; 116:651-3
214. Ozyazgan Y, Yurdakul S, Yazici H, et al, Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 1992; 76: 241-3
215. Pacor ML, Biasi D, Lunardi C. et al. Cyclosporin in Behçet's disease: results in 16 patients after 24 months of therapy. Clin Rheumatol 1994; 13: 224-7
216. Fauci AS, Katz P, Haynes BF, et al. Cyclophosphamide therapy of severe systemic necrotizmg vasculitis. N Engl J Med 1979: 301:234-8
217. Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 pa tients for 21 years. Ann Intern Med 1983; 98: 76-85
218. Hoffman GS, Kerr GS, Leavitt RY, et al, Wegener granulomatosis: an analysis of 158 patients [see comments]. Ann Intern Med 1992; 116:488-98
219. Hoffman GS, Leavitt RY, Fleisher TA, et al, Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89: 403-10
220. Drosos A, Sakkas LI, Goussia A, et al, Pulse cyclophosphamide therapy in Wegener's granulomatosis: a pilot study. J Intern Med 1992; 232: 279-82
221. Genereau T, Lortholary O, Leclerq P et al, Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high-dose regimen in four patients, Br J Rheumatol 1994; 33: 959-62
222. Reinhold KE, Kekow J, Schnabel A, et al, Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994; 37:919-24
223. Jorizzo JL, White WL, Wise CM, et al, Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet's disease. J Am Acad Dermatol 1991; 24: 697-702
224. Alien NB, Caldwell DS, Rice JR, et al, Cyclosporin A therapy for Wegener's granulomatosis. Adv Exp Med Biol 1993; 336: 473-6
225. Stack PS, Methotrexate for urticarial vasculitis. Ann Allergy 1994; 72: 36-8
226. Hoffman GS, Leavitt RY, Kerr GS, et al, Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-82
227. Hoffman GS, Leavitt RY, Kerr GS, et al, The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35: 1322-9
228. Barker JNWN, The immunopathology of psoriasis. Bailliere's Clin Rheumatol 1994; 8: 429-38
229. Valdimarsson H, Baker BS, Jonsdottir I, et al, Psoriasis: a T-cell mediated autoimmune disease induced by streptococcal antigens? Immunol Today 1995; 16: 145-9
230. Bata-Csorgo Z, Hammerberg C, Vorhees JJ, et al, Kinetics and regulation of human keratinocyte stem cell growth in shortterm primary ex-vivo culture. J Clin Invest 1995; 95: 317-27
231. Gottlieb SL, Gilleaudeau P, Johnson R, et al, Response of psoriasis to a lymphocyte-selective toxin (DABj89lL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1995; 1:442-7
232. du Vivier A, Monro D, Verbov J, Treatment of psoriasis with azathioprine. BMJ 1974; 1:49-51
233. Hacker SM, Ramos CF, Ford MJ, et al, Azathioprine: a forgotten alternative for treatment of severe psoriasis. Int J Dermatol 1992; 31: 873-4
234. McDonald CJ, Cylotoxic agents for use in dermatology. I. J Am Acad Dermatol 1985; 12: 753-75
235. Rosenbaum M, Roenigk HJ, Treatment of generalized pustular psoriasis with etretinate (Ro-10-9359) and methotrexate. J Am Acad Dermatol 1984; 12: 357
236. Griffiths CEM, Powles AV, Leonard JN, et al, Clearance of psoriasis with low dose cyclosporin. BMJ 1986; 293: 731-2
237. Ellis CN, Fradin MS, Messana JM, et al, Cyclosporin for plaque-type psoriasis. N Engl J Med 1991; 324: 277-84
238. Gerritsen MJP, Rulo HFC, Arnold WP, et al, Response of the clinically uninvolved skin of psoriatic patients to repeated tape stripping during cyclosporin A treatment. Br J Dermatol 1994; 130: 181-8
239. Reitamo S, Erkko P, Retnitz A, et al, Cyclosporin in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study [see comments]. Arch Dermalol 1993; 129:1273-9
240. Ellis CM, Fradin MS, Hamilton TA, et al, Duration of remission during maintenance cyclosporin therapy for psoriasis. Arch Dermatol 1995; 131: 791-5
241. Laburte C, Grossman R, Abi-Rached J, et al, Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130: 366-75
242. Weinstein GD, White GM, An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454-9
243. Peluso AM, Bardazzi F, Tosti A, et al, Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients. Acta Derm Venereol Suppl (Stockh) 1994; 186: 90-1
244. Korstanje MJ, Van de Staak WJBM, Combination-therapy cyclosporin-A-etretinate for psoriasis. Clin Exp Dermatol 1990; 15: 172-3
245. Grossman RM, Thivolet J, Claudy A, et al, A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporin: results of a multicenter placebocontrolled study. J Am Acad Dermatol 1994; 31: 68-74
246. Klein LR, Callen if, Azathioprine: effective steroid-sparing therapy for generalized lichen planus. South Med J 1992; 85: 198-201
247. August PJ, Wells GC, Pyoderma gangrenosum treated with azathioprine and prednisolone. Br J Dermatol 1974; 91 Suppl. 10:80
248. tally EV, Ho GA, A review of methotrexate therapy in Reiter's Syndrome. Semin Arthitis Rheum 1985; 15: 139-45
249. Lynch P, Saied N, Methotrexate treatment of pityriasis lichenoides and lymphomatoid papulosis. Cutis 1979; 23:634
250. Lopez Estebaranz JL, Vanaclocha F, Gil R, et al, Febrile ulceronecrotic Mucha-Habermann disease [review]. J Am Acad Dermatol 1993:29:903-6
251. Everett M, Treatment of lymphomatoid papulosis with methotrexate. Br J Dermatol 1984; 111: 631
252. Knowles WR, Chernosky ME, Pityrisis rubra pilaris: prolonged treatment with methotrexate. Arch Dermatol 1970; 102: 603-12
253. Dicken CH, Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol 1994; 31: 997-9
254. Webster GF, Razsi LK, Sanchez M, et al, Methotrexate therapy in cutaneous sarcoidosis. Ann Intern Med 1990; 111: 538-9
255. Webster GF, Razsi LK, Sanchez M, et al, Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991; 24: 451-4
256. Mathur A, Kremer JM, Immunopathology, rheumatic features, and therapy of sarcoidosis [review]. Curr Opin Rheumatol 1992;4:76-80
257. Suda T, Sato A, Toyoshima M, et al, Weekly low-dose methotrexate therapy for sarcoidosis. Intern Med 1994; 33: 437-40
258. Curley RK, MacFarlane AW, Vickers CFH, Pyoderma gangrenosum treated with cyclosporin A. Br J Dermatol 1985; 113:601-4
259. Penmetcha M, Navaratnam A, Pyoderma gangrenosum: response to cyclosporin A. Int J Dermatol 1988; 27: 253
260. Shelley ED, Shelley WB, Cyclosporin therapy for pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis. J Am Acad Dermatol 1988; 18: 1084-8
261. Bijmer-lest JC, Rompelman-Schiere SM, Van Ginkel CJW, Treatment of pyoderma gangrenosum with cyclosporin. Br J Dermatol 1991; 125: 283
262. O'Donnell B, Powell FC, Cyclosporin treatment of pyoderma gangrenosum. J Am Acad Dermatol 1991; 24: 141-3
263. Soria C, Allègue F, Martin M, et al, Treatment of pyoderma gangrenosum with cyclosporin A. Clin Exp Dermatol 1991; 16: 392-4
264. Kavanagh CM, Ross JS, Cronin E, et al, Recalcitrant pyoderma gangrenosum - two cases successfully treated with cyclosporin A. Clin Exp Dermatol 1992; 17: 49-52
265. Fedi MC, Quercetani R, Lotti T. Recalcitrant pyoderma gangrenosum responsive to cyclosporin. Int J Dermatol 1993; 32: 119
266. Elgart G, Stover P, Larson K, et al, Treatment of pyoderma gangrenosum with cyclosporin: results in seven patients. J Am Acad Dermatol 1991; 24: 83-6
267. Malis WL, Ellis CN, Griffiths CE, et al, Treatment of pyoderma gangrenosum with cyclosporin. Arch Dermatol 1992; 128: 106(1-4
268. Ho VC, Gupta AK, Ellis CN. et al. Treatment of severe lichen planus with cyelosporin. J Am Acad Dermatol 1990; 22: 64-8
269. ReiffersMettelock J, Acute lichen planus treated by Sandimmun (ciclosporin) [letter]. Dermatology 1992; 184: 84
270. Levell NJ, Munro CS, Marks JM. Severe lichen planus clears with very low-dose cyelosporin [letter]. BrJ Dermatol 1992; 127:66-7
271. Eisen D, Ellis CN, Duell EA, et al, Effect of topical cyelosporin rinse on oral lichen planus - a double-blind analysis. N Eng! J Med 1990:323: 290-4
272. Borrego L, Ruiz-Rodriguez R, OrtizdeFrutos J, et al. Vulvar lichen planus treated with topical cyelosporin [letter]. Arch Dermatol 1993: 129:794